EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants

Ryota Jin iD, Hideki Yoshioka iD, Hiromi Sato iD, Akihiro Hisaka iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Ryota Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As Parkinson's disease (PD) progresses, there are multiple biomarker changes, and sex and genetic variants may influence the rate of progression. Data‐driven, long‐term disease progression model analysis may provide precise knowledge of the relationships between these risk factors and progression and would allow for the selection of appropriate diagnosis and treatment according to disease progression. To construct a long‐term disease progression model of PD based on multiple biomarkers and evaluate the effects of sex and leucine‐rich repeat kinase 2 (LRRK2) mutations, a technique derived from the nonlinear mixed‐effects model (Statistical Restoration of Fragmented Time course [SReFT]) was applied to datasets of patients provided by the Parkinson's Progression Markers Initiative. Four biomarkers, including the Unified PD Rating Scale, were used, and a covariate analysis was performed to investigate the effects of sex and LRRK2‐related mutations. A model of disease progression over ~30 years was successfully developed using patient data with a median of 6 years. Covariate analysis suggested that female sex and LRRK2 G2019S mutations were associated with 21.6% and 25.4% significantly slower progression, respectively. LRRK2 rs76904798 mutation also tended to delay disease progression by 10.4% but the difference was not significant. In conclusion, a long‐term PD progression model was successfully constructed using SReFT from relatively short‐term individual patient observations and depicted nonlinear changes in relevant biomarkers and their covariates, including sex and genetic variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansFemaleLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationBiomarkersDisease Progression

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Biomarkers

Autor:innen und Institutionen

  • Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.

ORCID-Profile: Ryota Jin, Hideki Yoshioka, Hiromi Sato, Akihiro Hisaka

Zitieren

APA

Jin, R., Yoshioka, H., Sato, H., & Hisaka, A. (2024). Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13112

Vancouver

Jin R, Yoshioka H, Sato H, Hisaka A. Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13112

BibTeX
@article{Jin2024,
  author = {Jin, Ryota and Yoshioka, Hideki and Sato, Hiromi and Hisaka, Akihiro},
  title = {Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13112}
}
Kostenlos starten →